Law firm Bragar Eagel & Squire investigates potential claims against RAPT Therapeutics for alleged federal securities law violations and unlawful practices related to their Phase 2b and 2a trials.
Law firm Bragar Eagel & Squire is investigating potential claims against RAPT Therapeutics, Inc. on behalf of RAPT stockholders, concerning whether the company violated federal securities laws or engaged in unlawful business practices. RAPT announced on Feb 20 that the US FDA verbally notified a clinical hold on their Phase 2b trial of zelnecirnon in atopic dermatitis and Phase 2a trial in asthma. The firm encourages investors who purchased RAPT shares and suffered losses to contact them.
March 11, 2024
3 Articles